top of page
Nevia bio
Nevia site photo.png

Early Detection of Gynecologic Cancers Through Vaginal Fluid Analysis

Starting with ovarian cancer:
a lethal, aggressive cancer that strikes without warnings

Our Services

Who we are

Women • Health • First

Nevia Bio is a diagnostics company focused on transforming early detection, monitoring and treatment guidance for gynecological cancers. By harnessing the unique biological properties of vaginal fluid as a liquid biopsy, we aim to deliver earlier, more accurate, and more accessible diagnostic solutions—starting with ovarian cancer and expanding to the full spectrum of gynecological malignancies.  

​

Using AI and multi-omics approach, we are challenging conventional assumptions in cancer care and pioneer a novel, proximity-based, non-invasive approach that gives women better outcomes, more time, and greater agency over their health. 

Our
Solution

Swab
Biomarkers

Simple vaginal swab

Biomarkers data

Nevia Bio uses vaginal fluid—not blood—to detect gynecologic cancers earlier and more accurately. By analyzing the fluid nearest to the tumor site, rather than waiting for cancer DNA to appear in blood, we aim to uncover disease much sooner.
Our test is designed for self-collection, eliminating the need for blood draws, clinical visits, or invasive procedures. The result: earlier and more accurate detection, with lower cost and higher convenience

Data base
Identify patients

Machine learning

Identify patients

Contact

TEAM

  • LinkedIn
Nicole-small.JPG
  • LinkedIn

CEO

Director of Partnerships

  • LinkedIn
WhatsApp Image 2024-12-31 at 12.13_edite
Shiri Blumenfeld Kan

Scientific Project Manager &
Regulatory Affairs Specialist

Dekel Gelbman, LL.B, MBA

Shiri Blumenfeld Kan, PhD, MBA

Nicole Fleischer, BSc, MBA

Valeria_new_edited.jpg
IMG_1848_edited.jpg
  • LinkedIn
  • LinkedIn
IMG_2488_edited.jpg
  • LinkedIn

Clinial Operations Manager

Valeria Miller, BSc, MBA

Senior Scientist, Life Science

Yael Teboul, MSc

Senior Data Scientist

Zohar Shnaider, BSc 

Board of Directors

Anula Jayasuriya
  • LinkedIn
Shlomit Yehudai Reshef
  • LinkedIn
Inbal Zafir Lavie
  • LinkedIn

Chair of the board

Founder, CSO & Director

Anula Jayasuriya MD, PhD, MBA

 

Shlomit Yehudai Reshef, PhD

Director & Co-founder

Inbal Zafir Lavie, PhD

Orna berry_edited.jpg

Board member

Dr. Orna Berry

Dan Shwarzman

Board member

Dan Shwarzman

IrisBeck.jpg

Board observer

Iris Beck

HilaKarah.jpg

Board observer

Hila Karah

Scientific Advisory Board

Prof. Rob Coleman
Prof. Brian Slomovitz

Prof. Rob Coleman

Chief Medical Officer, Vaniam Group, GOG Partners, Special Advisor to the President, GOG Foundation, Board Of Directors

Prof. Brian Slomovitz

Director, Gynecologic Oncology and Co-Chair, Cancer Research Committee, Mount Sinai Medical Center, Board of Directors and Uterine Cancer Lead, GOG Foundation

Prof. Ruth Peretz

Prof. Ruth Perets

Medical Oncologist and Head of the Women's Cancers Research Lab at Rambam Health Care Campus. Directs the Phase 1 Clinical Trials in Oncology 

Prof. Eitan Friedman

Prof. Eitan Friedman

Director and founder of the The Suzanne Levy-Gertner Oncogenetics Unit at the Sheba Medical Center

Why Us

Part of Israel's Innovation Dream Team Exabition at The Peres Center For Peace & Innovation

Mass Challenge winner

First Place Pitch Competition

Samsung Next

HLTH Diverse founders

Frost and Salivan

Israeli femtech innovation leadership award

Marker

Top 20 most promising companies

Career opportunities

General Application

We are always happy to hear from talented team players

Contact Us
Nevia bio

Thank you for contacting us!

bottom of page